

Liste des arrêts américains
concernant
la responsabilité
des sociétés pharmaceutiques et biotechnologiques cotées en bourse
vis-à-vis de leurs investisseurs
pour défaut d'information
- 10(b)(5) -
(classés par date)

2004

In re **Alpharma** Inc. Securities Litigation, 372 F.3d 137 (3rd Cir. 2004)

In re Bayer AG Securities Litigation, U.S. District Court for the Southern District of New York (September 30, 2004).

Asher v. **Baxter** International Inc. 377 F.3d 727 (7th Cir. 2004).

In re Bristol-Myers Squibb Securities Litigation, 312 F. Supp. 3d 549 (U.S. District Court for the Southern District of New York, 2004)

In re **Corning**, Inc. Securities Litigation, 2004 U.S. Dist. LEXIS 25624 (S.D.N.Y. 2004)

In re CV Therapeutics Inc. Securities Litigation, 2004 U.S. Dist. LEXIS 17419 (Aug.5, 2004, U.S. District Court for the Northern District of California).

In re **Elan** Corp. Securities Litigation, 2004 U.S. Dist. LEXIS 9913 (S.D.N.Y. 2004)

In re **Guidant** Corp. Securities Litigation, 2004 U.S. Lexis 22809 (S.D. Ind. 2004).

In re **ICN** Pharmaceuticals, Inc. Securities Litigation, 299 F.Supp.2d 1055 (C.D.Cal. 2004)

In re **Intermune**, Inc. Securities Litigation, 2004 U.S. Dist. LEXIS 15382 (N.D.Cal. 2004).

In re **Sepracor**, Inc. Securities Litigation, 308 F. Supp. 2d 20 (2004, D.C.Mass).

In re **Transkaryotic Therapies**, Inc. Securities Litigation, 319 F. Supp. 2d 152 (D.C.Mass. May 26, 2004).

2003

In re **Alliance Pharmaceutical** Corp. Securities Litigation, 279 F. Supp. 2d 171 (S.D.N.Y. 2003).

In re **Amylin** Pharmaceuticals, Inc. Securities Litigations, 2003 U.S. Dist. LEXIS 7667 (S.D.Cal. 2003).

In re **Andrx** Corporation, Inc. v. Taztia XT Securities Litigation, 296 F. Supp.2d (S.D.Flor. 2003).

In re **Bausch & Lomb**, Inc. Securities Litigation, 2003 U.S. Dist. LEXIS 24062 (W.D.N.Y. 2003)

Broudo v. Dura Pharmaceuticals Inc., 339 F.3d 933 (9th Cir. 2003)

In re **Empyrean** Bioscience, Inc. Securities Litigation, 255 F.Supp. 2d 751 (N.D.Oh. 2003)

Martin v. Maxim Pharmaceuticals, Inc. ____, (S.D.Cal. 2003)

In re **Neopharm**, Inc. Securities Litigation (2003 U.S. Dist. LEXIS 1862 (n.d.Ill. 2003)

In re **Viropharm**, Inc. Securities Litigation, 2003 U.S. Dist. LEXIS 5623 (E.D.Penn. 2003)

2002

Meyer v. Biopure Corp., 221 F.Supp. 2d 195 (D.C.Mass. 2002)

In re **Noven** Pharmaceuticals, Inc. Securities Litigation, 238 F.Supp.2d 1315 (S.D.Fl. 2002)

In re **Ribozyme** Pharmaceuticals Inc. Securities Litigation, 209 F Supp. 2d 1106 (D.Col. 2002)

2001

Gallagher v. **Abbott** Laboratories, 269 F.3d 806 (7th Cir. 2001)

Anderson v. **Abbott** Laboratories, 140 F.Supp. 2d 894 (N.D.Ill. 2001)

Nathenson v. **Zonagen** Inc., 267 F.3d 400 (5th Cir. 2001)

In re **Columbia** Laboratories, Inc. Securities Litigation, 144 F. Supp. 2d 1362 (S.D.Flo. 2001).

DeMarco v. **Depotech**, 149 F. Supp. 2d 1212 (S.D.Cal. 2001)

In re **SI** Corporation Securities Litigation, 173 F. Supp. 2d 1334 (N.D.Geor. 2001)

In re **Technical Chemicals** Securities Litigation, 2001 u.S. Dist. LEXIS 4851 (S.D.Flo. 2001).
Précédemment: 2000 U.S. Dist. LEXIS 11739 (S.D.Flo 2000)

2000

Oran v. **American Home Products** Corp., 226 F.3d 275 (2000, 3rd Cir.).

Chu v. **Sabratek** Corp., 100 F.Supp. 2d 827 (N.D.Ill. 2000)

In re **Cell Pathways**, Inc. Securities Litigation, 2000 U.S. Dist. LEXIS 8584 (E.D.Penn. 2000)

In re **Carter-Wallace** Securities Litigation,
220 F.3d 36 (2nd Cir. 2000).
1999 U.S. Dist. LEXIS 17526 (S.D.N.Y. 1999).
150 F.3d 153 (2nd Cir.1998)

In re **Dura** Pharmaceuticals, Inc. Securities Litigation, 2000 U.S. Dist. LEXIS 15258 (S.D.Cal. 2000)

In re **Ultrafem** Inc. Securities Litigation, 92 F. Supp. 2d 678 (S.D.N.Y. 2000).

Pre-2000

In re **PLC Systems Inc.** Securities Litigation, 41 F. Supp. 2d 106 (D.Mass. 1999).

Harris v. **IVAX Corp.**, 998 F.Supp. 1449 (S.D.Flo. 1998).

In re **Biogen** Securities Litigation, 179 F.R.D. 25 (D.C.Mass. 1997)

In re **Syntex Corp.** Securities Litigation, 95 F.3d 922 (9th Cir. 1996)

Pre-PSLRA

In re **Sofamor Danek Group**, 123 F.3d 394 (6th Cir. 1997)

Warshaw v. **Xoma Corp.**, 74 F.3d 955 (9th Cir. 1996)

In re Regeneron Pharmaceuticals Securities Litigation, (U.S. District Court for the Southern District of New York 1995).

In re **Medimmune, Inc.** Securities Litigations, 873 F. Supp. 953 (D.Mar. 1995).

Robbins v. **Moore Medical Corp.**, 894 F.Supp. 661 (S.D.N.Y. 1995)

In re **Cryomedical Sciences, Inc.** Securities Litigation, 884 F.Supp. 1001 (S.D.Md. 1995)

Acito v. **Imcera Group, Inc.**, 47 F.3d 47 (2nd Cir. 1995)

Steiner v. **Gensia Pharmaceuticals, Inc.** 868 F.Supp. 284 (S.D.Cal. 1994)

In re **Synergen** Securities Litigation, 863 F.Supp. 1409 (D.Col. 1994)

In re **Abbott Laboratories** Securities Litigation, 1993 U.S. Dist LEXIS 6033 (N.D. Ill. 1993)

Westwood v. **Barr Laboratories, Inc.** 838 F.Supp. 126 (S.D.N.Y. 1993)

In re **Zenith Laboratories** Securities Litigation (1993 U.S. Dist. LEXIS 18478 (D.N.J. 1993)

Ballan v. The **Upjohn Company**, 814 F.Supp.1375 (W.D.Mich. 1992)

Robbins v. **Moore Medical Corp.**, 788 F.Supp.179 (S.D.N.Y. 1992)

Morse v. **Abbott Laboratories**, 756 F.Supp.1108 (N.D.Ill. 1991).

In re **Par Pharmaceutical, Inc.** Securities Litigation, 733 F.Supp. 668 (S.D.N.Y. 1990)